<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27737405</article-id><article-id pub-id-type="pmc">5062710</article-id><article-id pub-id-type="doi">10.5935/1678-9741.20160054</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Methylene Blue to Treat Protamine-induced Anaphylaxis Reactions. An
Experimental Study in Pigs</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Albuquerque</surname><given-names>Agnes Afrodite S.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>BsC</role></contrib><contrib contrib-type="author"><name><surname>Margarido</surname><given-names>Edson A.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Menardi</surname><given-names>Antonio Carlos</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Scorzoni Filho</surname><given-names>Adilson</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Celotto</surname><given-names>Andrea Carla</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>BsC, PhD</role></contrib><contrib contrib-type="author"><name><surname>Rodrigues</surname><given-names>Alfredo J.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Vicente</surname><given-names>Walter Vilella A.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Evora</surname><given-names>Paulo Roberto B.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD, PhD</role></contrib><aff id="aff1"><label>1</label>Laboratory of Endothelium and Cardiovascular
Function; Department of Surgery and Anatomy, Faculdade de Medicina de
Ribeir&#x000e3;o Preto da Universidade de S&#x000e3;o Paulo (FMRP-USP), SP,
Brazil. </aff></contrib-group><author-notes><corresp id="c1"><bold>Correspondence Address:</bold> Paulo Roberto B. Evora,
Faculdade de Medicina de Ribeir&#x000e3;o Preto da Universidade de S&#x000e3;o
Paulo, Department of Surgery and Anatomy, Av. Bandeirantes, 3900,
Ribeir&#x000e3;o Preto, SP, Brazil - Zip code: 14048-900. E-mail:
<email>prbevora@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>May-Jun</season><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>May-Jun</season><year>2016</year></pub-date><volume>31</volume><issue>3</issue><fpage>226</fpage><lpage>231</lpage><history><date date-type="received"><day>01</day><month>7</month><year>2016</year></date><date date-type="accepted"><day>30</day><month>7</month><year>2016</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>OBJECTIVE:</title><p>To examine if methylene blue (MB) can counteract or prevent protamine (P)
cardiovascular effects.</p></sec><sec><title>METHODS:</title><p>The protocol included five heparinized pig groups: Group Sham -without any
drug; Group MB - MB 3 mg/kg infusion; Group P - protamine; Group P/MB - MB
after protamine; Group MB/P - MB before protamine. Nitric oxide levels were
obtained by the nitric oxide/ozone chemiluminescence method, performed using
the Nitric Oxide Analizer 280i (Sievers, Boulder, CO, USA). Malondialdehyde
plasma levels were estimated using the thiobarbiturate technique.</p></sec><sec><title>RESULTS:</title><p>1) Groups Sham and MB presented unchanged parameters; 2) Group P - a)
Intravenous protamine infusion caused mean arterial pressure decrease and
recovery trend after 25-30 minutes, b) Cardiac output decreased and remained
stable until the end of protamine injection, and c) Sustained systemic
vascular resistance increased until the end of protamine injection; 3)
Methylene blue infusion after protamine (Group P/MB) - a) Marked mean
arterial pressure decreased after protamine, but recovery after methylene
blue injection, b) Cardiac output decreased after protamine infusion,
recovering after methylene blue infusion, and c) Sustained systemic vascular
resistance increased after protamine infusion and methylene blue injections;
4) Methylene blue infusion before protamine (Group MB/P) - a) Mean arterial
pressure decrease was less severe with rapid recovery, b) After methylene
blue, there was a progressive cardiac output increase up to protamine
injection, when cardiac output decreased, and c) Sustained systemic vascular
resistance decreased after protamine, followed by immediate Sustained
systemic vascular resistance increase; 5) Plasma nitrite/nitrate and
malondialdehyde values did not differ among the experimental groups.</p></sec><sec><title>CONCLUSION:</title><p>Reviewing these experimental results and our clinical experience, we suggest
methylene blue safely prevents and treats hemodynamic protamine
complications, from the endothelium function point of view.</p></sec></abstract><kwd-group><kwd>Protamines</kwd><kwd>Nitric Oxide</kwd><kwd>Methylene Blue</kwd><kwd>Anaphylaxis</kwd></kwd-group></article-meta></front><body><p><table-wrap id="t1" orientation="portrait" position="anchor"><table frame="hsides" rules="groups" style="background-color:#e6e7e8"><colgroup span="1"><col width="15%" span="1"/><col width="85%" span="1"/></colgroup><thead><tr><th colspan="2" align="left" rowspan="1"><bold>Abbreviations, acronyms &#x00026;
symbols</bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">CO</td><td rowspan="1" colspan="1">= Cardiac output</td></tr><tr><td rowspan="1" colspan="1">CVP</td><td rowspan="1" colspan="1">= Central venous pressure</td></tr><tr><td rowspan="1" colspan="1">MAP</td><td rowspan="1" colspan="1">= Mean arterial pressure</td></tr><tr><td rowspan="1" colspan="1">MB</td><td rowspan="1" colspan="1">= Methylene blue</td></tr><tr><td rowspan="1" colspan="1">MDA</td><td rowspan="1" colspan="1">= Malondialdehyde</td></tr><tr><td rowspan="1" colspan="1">NO</td><td rowspan="1" colspan="1">= Nitric oxide</td></tr><tr><td rowspan="1" colspan="1">NOx</td><td rowspan="1" colspan="1">= Nitrite/nitrate</td></tr><tr><td rowspan="1" colspan="1">PAP</td><td rowspan="1" colspan="1">= Pulmonary arterial pressure</td></tr><tr><td rowspan="1" colspan="1">PCP</td><td rowspan="1" colspan="1">= Pulmonary capillary pressure</td></tr><tr><td rowspan="1" colspan="1">PVR</td><td rowspan="1" colspan="1">= Pulmonary vascular resistance</td></tr><tr><td rowspan="1" colspan="1">SEM</td><td rowspan="1" colspan="1">= Standard error of the mean</td></tr><tr><td rowspan="1" colspan="1">SVR</td><td rowspan="1" colspan="1">= Systemic vascular resistance</td></tr></tbody></table></table-wrap>
</p><sec sec-type="intro"><title>INTRODUCTION</title><p>Clinical and experimental observations prove that heparinneutralizing doses of
protamine increase pulmonary artery pressures and decrease systemic blood pressure.
Protamine also increases myocardial oxygen consumption, cardiac output (CO), and
heart rate, and decreases systemic vascular resistance. These cardiovascular effects
have clinical consequences that have justified studies in this area. Protamine
adverse reactions usually can be classified into three different categories, namely:
systemic hypotension, anaphylactoid reactions, and catastrophic pulmonary
vasoconstriction. The precise mechanism that explains protamine-mediated systemic
hypotension is unknown. Four experimental protocols performed at Mayo Clinic
(Rochester, MN, USA) studied the intrinsic mechanism of protamine vasodilation. The
first study reported <italic>in vitro</italic> systemic and coronary vasodilation
after protamine infusion<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. The
second <italic>in vitro</italic> study suggested that pulmonary circulation is
extensively involved in the protamine-mediated effects on endothelial
function<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. The third
study, carried out in anesthetized dogs, reported the methylene blue (MB) and nitric
oxide (NO) synthase blockers neutralization of the protamine vasodilatory
effects<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup> The fourth study
proposed that protamine also causes endothelium-dependent vasodilation in heart
microvessels and conductance arteries by different mechanisms, including
hyperpolarization<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>.
Reviewing those experimental results and our clinical experience, we suggest MB as a
novel approach to prevent and treat hemodynamic complications caused by the use of
protamine after cardiopulmonary bypass<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>.</p><p>In the absence of prospective clinical trials and cumulative clinical evidence, based
on the literature case reports, the present study was carried out to examine if MB
can counteract or prevent protamine cardiovascular effects.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Experimental design</title><p>The protocol included five heparinized pig groups: Group Sham - without any drug;
Group MB - MB 3 mg/kg infusion; Group P - protamine; Group P/MB - MB after
protamine; Group MB/P - MB before protamine. NO plasma levels were measured in
each of the experimental groups. The procedures and handling of the animals were
reviewed and approved by the Institutional Animal Care review board (Reg
142/2006).</p></sec><sec><title>Animal preparation and hemodynamic parameters</title><p>Female Dalland pigs (22-26 kg) were induced to anesthesia with intramuscular
administration of midazolam (15 mg/kg, Dormid<sup>&#x000ae;</sup>,
Crist&#x000e1;lia Produtos Qu&#x000ed;micos Ltda., SP, Brazil) and
tiletamine/zolazepam (10 mg/kg, Telazol<sup>&#x000ae;</sup>, Fort Dodge, IA,
USA). Maintenance was achieved by total intravenous anesthesia using sufentanil
(100 &#x000b5;g/h, Fastfan<sup>&#x000ae;</sup>, Crist&#x000e1;lia Produtos
Qu&#x000ed;micos Ltda., SP, Brazil) and propofol (10 mg/kg/h,
Propovan<sup>&#x000ae;</sup>, Crist&#x000e1;lia Produtos Qu&#x000ed;micos
Ltda., SP, Brazil) delivered by syringe infusion pump (Syringe Infusion Pump,
Harvard Apparatus, MA, USA). Pancuronium bromide (6 mg/h,
Pancuron<sup>&#x000ae;</sup>, Crist&#x000e1;lia Produtos Qu&#x000ed;micos
Ltda., SP, Brazil) was used as a muscle relaxant. Tracheostomy was performed on
all animals immediately after induction of anesthesia. Volemia maintenance was
achieved with intravenous infusion of sodium chloride 0.9% (5 mL/kg/h). A
Swan-Ganz CCOmbo CCO/SvO<sub>2</sub> 744HF75 (Edwards Lifesciences, CA, USA)
catheter was placed in the right jugular vein and into the lumen of the main
pulmonary artery. The left carotid artery was simultaneously catheterized. Mean
arterial pressure (MAP), pulmonary arterial pressure (PAP), pulmonary capillary
pressure (PCP) and central venous pressure (CVP) were recorded by the MP System
100 A (BioPac System, Inc., CA, USA). Cardiac output (CO), systemic vascular
resistance (SVR) and pulmonary vascular resistance (PVR) were obtained by the
Vigilance System (Edwards Lifesciences LLC, CA, USA). After instrumentation, a
period of 20 minutes was allowed for anesthesia stabilization. After that,
hemodynamic parameters and clinical conditions were recorded for 15 minutes.</p></sec><sec><title>Statistical analysis</title><p>The hemodynamic results were expressed as mean &#x000b1; standard error of the
mean (SEM) and analysis of variance (Twoway ANOVA) and Bonferroni post-test. The
Nitrite/Nitrate (NOx) and malondialdehyde (MDA) results were analyzed using
paired T-test (Prism 5.0, GraphPad Software Inc., San Diego, CA, USA). Values
are considered to be statistically significant at <italic>P</italic> values
smaller than 0.05.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Mean arterial pressure (MAP)</title><p>Groups Sham, MB and P showed unchanged parameters. Intravenous P infusion caused
MAP drop followed by a recovery trend after 25-30 minutes. The MAP curves of
Sham, P and MB were not different and the effect was considered not quite
significant (<italic>P</italic>=0.05) (<xref ref-type="fig" rid="f1">Figure
1A</xref>).</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Mean arterial pressure (n=6, Two-way ANOVA. Bonferroni post-test.
P&#x0003c;0.05). MAP=mean arterial pressure; MB=methylene blue;
P=protamine</p></caption><graphic xlink:href="rbccv-31-03-0226-g01"/></fig>
</p><p>In the MB infusion before protamine group (Group MB/P), the drop in MAP was less
severe, with rapid recovery. In MB infusion after protamine group (Group P/MB),
marked MAP decrease after protamine was observed, with recovery after MB
injection. The curves of P, P/MB and MB/P groups were not different and the
effect was not significant (<italic>P</italic>=0.3786) (<xref ref-type="fig" rid="f1">Figure 1B</xref>).</p></sec><sec><title>Cardiac output (CO)</title><p>Groups Sham, P and MB showed unchanged parameters (n=6;
<italic>P</italic>&#x0003e;0.05). The statistical significance was borderline and the
software pointed out that a larger number of animals would improve the data. In
Group P, CO decreased and remained stable until the end of the protamine
injection (<xref ref-type="fig" rid="f2">Figure 2A</xref>).</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Cardiac output (n=6, Two-way ANOVA. Bonferroni post-test. P&#x0003c;.05).
CO=cardiac output; MB=methylene blue; P=protamine</p></caption><graphic xlink:href="rbccv-31-03-0226-g02"/></fig>
</p><p>In Group P/MB, CO decreased after protamine infusion, recovering after MB
infusion. In the Protamine after MB group, there was a progressive CO increase
to the time of protamine injection, when CO decreased. In addition, the curves
of <italic>P</italic>, P/MB and MB/P were different and presented statistical
difference (<italic>P</italic>&#x0003c;0.05) between groups P and MB/P at 30 minutes
(<xref ref-type="fig" rid="f2">Figure 2B</xref>).</p></sec><sec><title>Systemic vascular resistance (SVR)</title><p>Groups Sham and MB showed unchanged parameters. Group P sustained an SVR increase
until the end of the protamine injection. The SVR curves of Sham, P and MB were
different and presented statistical difference (<italic>P</italic>&#x0003c;0.01)
between groups P and Sham at 35 and 40 minutes (<xref ref-type="fig" rid="f3">Figure 3A</xref>).</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Systemic vascular resistance (n=6, Two-way ANOVA. Bonferroni
post-test. P&#x0003c;0.05). SVR=systemic vascular resistance;
MB=methylene blue; P=protamine</p></caption><graphic xlink:href="rbccv-31-03-0226-g03"/></fig>
</p><p>Group P/MB sustained SVR increase after P and MB injections and in Group MB/P,
the SVR dropped after protamine followed by immediate SVR increase. Moreover,
there was statistical difference (<italic>P</italic>&#x0003c;0.05) between group P
<italic>versus</italic> P/MB and P <italic>versus</italic> MB/P at 40
minutes (<xref ref-type="fig" rid="f3">Figure 3B</xref>).</p></sec><sec><title>Pulmonary arterial pressure (PAP)</title><p>The PAP curves in the Sham, P and MB groups showed a statistically significant
increase (<italic>P</italic>&#x0003c;0.001) after protamine injection (15 minutes),
followed by immediate decrease (<xref ref-type="fig" rid="f4">Figure 4A</xref>).
Also, the curves of Groups P, P/MB and MB/P showed statistically significant
difference (<italic>P</italic>&#x0003c;0.01) between Group P versus P/MB and P
<italic>versus</italic> MB/P at 15 minutes (<xref ref-type="fig" rid="f4">Figure 4B</xref>).</p><p>
<fig id="f4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Pulmonary arterial pressure (n=6, Two-way ANOVA. Bonferroni
post-test. P&#x0003c;0.05). PAP=pulmonary artery pressure; MB=methylene
blue; P=protamine</p></caption><graphic xlink:href="rbccv-31-03-0226-g04"/></fig>
</p></sec><sec><title>Central venous pressure (CVP)</title><p>The CVP curves of Sham and MB remained stable during 40 minutes of experiment. On
the other hand, Group P presented an increase at minute 15, followed by
immediate decrease (<xref ref-type="fig" rid="f5">Figure 5A</xref>). The curve
in the MB/P group remained stable during 40 minutes of experiment and, P and
P/MB presented an increase at minute 15, followed by immediate decrease (<xref ref-type="fig" rid="f5">Figure 5B</xref>).</p><p>
<fig id="f5" orientation="portrait" position="float"><label>Fig. 5</label><caption><p>Central venous pressure (n=6, Two-way ANOVA. Bonferroni post-test.
P&#x0003c;0.05). CVP=central venous pressure; MB=methylene blue;
P=protamine</p></caption><graphic xlink:href="rbccv-31-03-0226-g05"/></fig>
</p></sec><sec><title>Plasma nitrite/nitrate (NOx)</title><p>Plasma NOx concentrations did not present statistically significant difference
(<xref ref-type="fig" rid="f6">Figure 6</xref>).</p><p>
<fig id="f6" orientation="portrait" position="float"><label>Fig. 6</label><caption><p>Plasma Nitrite/Nitrate (NOx) concentrations (n=6; t test.
P&#x0003c;0.05).</p></caption><graphic xlink:href="rbccv-31-03-0226-g06"/></fig>
</p></sec><sec><title>Malondialdehyde (MDA)</title><p>MDA concentrations did not present statistically significant difference (<xref ref-type="fig" rid="f7">Figure 7</xref>).</p><p>
<fig id="f7" orientation="portrait" position="float"><label>Fig. 7</label><caption><p>Malondialdehyde concentrations (n = 6; t test. P&#x0003c;0.05).</p></caption><graphic xlink:href="rbccv-31-03-0226-g07"/></fig>
</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Heparin/protamine interaction is a topic of interest due to its use during
cardiopulmonary bypass. These drugs are prescribed to more than 2,000,000 patients
every year. From clinical and experimental data, heparin-neutralizing doses of
protamine increase pulmonary artery pressures and decrease systemic blood pressure,
myocardial oxygen consumption, CO, heart rate, and SVR. Those cardiovascular effects
have clinical consequences that justified studies in this area.</p><p>Transitory hypotension in animals after protamine infusion has been observed as an
experimental effect for &#x0003e; 50 years<sup>[<xref rid="r6" ref-type="bibr">6</xref>-<xref rid="r8" ref-type="bibr">8</xref>]</sup>. However, until the
development of cardiac surgery, protamineinduced hypotension was an experimental
finding of little clinical relevance. As protamine became largely used in clinical
and surgical procedures, its reactions frequently led to severe systemic
hypotension, pulmonary hypertension, and shock<sup>[<xref rid="r9" ref-type="bibr">9</xref>-<xref rid="r13" ref-type="bibr">13</xref>]</sup>. Those
consequences can be potentially dangerous, especially immediately after
cardiopulmonary bypass, when intravascular volumes are not constant and cardiac
function may be impaired.</p><p>Protamine can also cause hemodynamic disturbance by means of anaphylactic
reactions<sup>[<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref>]</sup>.
Indeed, Horrow<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup> classified
protamine adverse reactions in three different categories: systemic hypotension,
anaphylactoid reactions, and catastrophic pulmonary vasoconstriction.</p><p>The precise mechanism that explains protamine-mediated systemic hypotension is
unknown. However, it is suggested that protamine decreases peripheral vascular
resistance rather than depressing myocardial function<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r17" ref-type="bibr">17</xref>]</sup>. Protamine sulfate (either as a free drug or complexed
with heparin) binds to an unidentified endothelial cell receptor that mediates the
conversion of L-arginine to NO. NO released abluminally activates soluble guanylate
cyclase in the vascular smooth muscle to induce cyclic GMP (cGMP)-mediated
relaxation (vasodilation). This results in a decrease in peripheral vascular
resistance and hypotension. NO released luminally would promote thrombolysis and
inhibit platelet adhesion in the blood vessel<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. Against this hypothesis, it is important to report that
Castresana et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>, using pig
vascular smooth muscle cell culture experiments, showed that protamine does not
alter the responses of the intracellular second messengers, cGMP and cAMP, to the
vasodilators sodium nitroprusside, atrial natriuretic peptide, isoproterenol, and
forskolin. Those results do not support the hypothesis that protamine sensitizes
vascular smooth muscle cells to the NO/endothelium-derived relaxing factor.
Favorable to the NO/endothelium-dependent mechanism, MB has been successfully used
to reverse protamine vasoplegic reactions in humans<sup>[<xref rid="r18" ref-type="bibr">18</xref>-<xref rid="r20" ref-type="bibr">20</xref>]</sup>.</p><p>For the endothelium-dependent vasodilatation in the pulmonary artery, a proposed
mechanism suggests that protamine sulfate binds to an unidentified endothelial cell
receptor to induce NO production from the amino acid L-arginine. NO then diffuses to
the underlying vascular smooth muscle to induce relaxation (vasodilatation). NO
released into the lumen would promote thombrolysis and inhibit platelet adhesion in
the blood vessel. The conversion of L-arginine to NO can be inhibited by
NG-monomethyl-L-arginine (L-NMMA), a methylated form of L-arginine. In addition,
differently from the systemic circulation, heparin can inhibit the ability of
protamine to induce NO, presumably by preventing the binding of protamine to
receptor<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. Favorable to
this hypothesis is the use of inhaled NO to control pulmonary
hypertension<sup>[<xref rid="r21" ref-type="bibr">21</xref>-<xref rid="r23" ref-type="bibr">23</xref>]</sup>.</p><p>Plasma NOx and indirect free radical activity estimated by measuring MDA levels
surprisingly did not show differences. Probably, the experimental time (40 minutes)
was not enough for the laboratory techniques to detect the possible stimulus for NO
release and free radical (lipidperoxidation) activity.</p><p>In conclusion, based on the results described, the following can be stated: 1)
Individual MB infusion did not change MAP, CO and SVR values whereas MB injected
before protamine attenuated the hypotension with rapid recovery and when injected
after protamine, it reversed the marked hypotension; 2) CO decreased after protamine
infusion, recovering after post-MB infusion, and MB infusion before protamine caused
a progressive CO increase, followed by attenuation at the time of protamine
injection; and 3) There was sustained SVR increase until the end of protamine
injection, decreased SVR after protamine, followed by immediate SVR increase when MB
was injected before protamine, and sustained SVR increase after protamine and post
MB injections. Reviewing these experimental results and our clinical experience, we
suggest that MB prevents and treats hemodynamic protamine complications.</p><p>Study limitations. It is mandatory to emphasize that the animals were not under
cardiopulmonary bypass that causes systemic inflammatory reaction, since this
reaction should exacerbate the hemodynamic effects of protamine. Other relevant
limitation is the number of animals used for each group (n=6), except for borderline
statistical significances, the statistical software pointed out that a larger number
of animals would improve the data.</p><p><table-wrap id="t2" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="15%" span="1"/><col width="85%" span="1"/></colgroup><thead><tr><th colspan="2" align="left" rowspan="1"><bold>Authors' roles &#x00026;
responsibilities</bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">AASA</td><td rowspan="1" colspan="1">Conception and study design; analysis and/or data
interpretation; statistical analysis; manuscript writing or
critical review of its content; final manuscript approval</td></tr><tr><td rowspan="1" colspan="1">EAM</td><td rowspan="1" colspan="1">Conception and study design; analysis and/or data
interpretation; final manuscript approval</td></tr><tr><td rowspan="1" colspan="1">ACM</td><td rowspan="1" colspan="1">Conception and study design; analysis and/or data
interpretation; final manuscript approval</td></tr><tr><td rowspan="1" colspan="1">ASF</td><td rowspan="1" colspan="1">Conception and study design; analysis and/or data
interpretation; final manuscript approval</td></tr><tr><td rowspan="1" colspan="1">ACC</td><td rowspan="1" colspan="1">Conception and study design; analysis and/or data
interpretation; final manuscript approval</td></tr><tr><td rowspan="1" colspan="1">AJR</td><td rowspan="1" colspan="1">Conception and study design; analysis and/or data
interpretation; final manuscript approval</td></tr><tr><td rowspan="1" colspan="1">WVAV</td><td rowspan="1" colspan="1">Conception and study design; analysis and/or data
interpretation; final manuscript approval</td></tr><tr><td rowspan="1" colspan="1">PRBE</td><td rowspan="1" colspan="1">Conception and study design; analysis and/or data
interpretation; statistical analysis; manuscript writing or
critical review of its content; final manuscript approval</td></tr></tbody></table></table-wrap>
</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn><fn fn-type="other"><p>This study was carried out at the Laboratory of Endothelium and Cardiovascular
Function; Department of Surgery and Anatomy, Faculdade de Medicina de Ribeir&#x000e3;o
Preto da Universidade de S&#x000e3;o Paulo (FMRP-USP), SP, Brazil.</p></fn><fn fn-type="supported-by"><p>No financial support.</p></fn></fn-group><ack><title>ACKNOWLEDGMENTS</title><p>CNPq, FAPESP, CAPES and FAEPA.</p></ack><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearson</surname><given-names>PJ</given-names></name><name><surname>Evora</surname><given-names>PR</given-names></name><name><surname>Ayrancioglu</surname><given-names>K</given-names></name><name><surname>Schaff</surname><given-names>HV</given-names></name></person-group><article-title>Protamine releases endothelium-derived relaxing factor from
systemic arteries: a possible mechanism of hypotension during heparin
neutralization</article-title><source>Circulation</source><year>1992</year><volume>86</volume><issue>1</issue><fpage>289</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">1617779</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evora</surname><given-names>PR</given-names></name><name><surname>Pearson</surname><given-names>PJ</given-names></name><name><surname>Schaff</surname><given-names>HV</given-names></name></person-group><article-title>Protamine induces endotheliumdependent vasodilation of the
pulmonary artery</article-title><source>Ann Thorac Surg</source><year>1995</year><volume>60</volume><issue>2</issue><fpage>405</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">7646104</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raikar</surname><given-names>GV</given-names></name><name><surname>Hisamochi</surname><given-names>K</given-names></name><name><surname>Raikar</surname><given-names>BL</given-names></name><name><surname>Schaff</surname><given-names>HV</given-names></name></person-group><article-title>Nitric oxide inhibition attenuates systemic hypotension produced
by protamine</article-title><source>Thorac Cardiovasc Surg</source><year>1996</year><volume>111</volume><issue>6</issue><fpage>1240</fpage><lpage>1246</lpage></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cable</surname><given-names>DG</given-names></name><name><surname>Sorajja</surname><given-names>P</given-names></name><name><surname>Oeltjen</surname><given-names>MR</given-names></name><name><surname>Schaff</surname><given-names>HV</given-names></name></person-group><article-title>Different effects of protamine on canine coronary microvessel and
conductance arteries: evidence of hyperpolarizing factor
release</article-title><source>Surgery</source><year>1999</year><volume>126</volume><issue>5</issue><fpage>835</fpage><lpage>841</lpage><pub-id pub-id-type="pmid">10568182</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viaro</surname><given-names>F</given-names></name><name><surname>Dalio</surname><given-names>MB</given-names></name><name><surname>Evora</surname><given-names>PR</given-names></name></person-group><article-title>Catastrophic cardiovascular adverse reactions to protamine are
nitric oxide/cyclic guanosine monophosphate dependent and endothelium
mediated: should methylene blue be the treatment of choice?</article-title><source>Chest</source><year>2002</year><volume>122</volume><issue>3</issue><fpage>1061</fpage><lpage>1066</lpage><pub-id pub-id-type="pmid">12226053</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marin-Neto</surname><given-names>JA</given-names></name><name><surname>Sykes</surname><given-names>MK</given-names></name><name><surname>Marin</surname><given-names>JL</given-names></name><name><surname>Orchard</surname><given-names>C</given-names></name><name><surname>Chakrabarti</surname><given-names>MK</given-names></name></person-group><article-title>Effect of heparin and protamine on left ventricular performance
in the dog</article-title><source>Cardiovasc Res</source><year>1979</year><volume>13</volume><issue>5</issue><fpage>254</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">476745</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaques</surname><given-names>LB</given-names></name></person-group><article-title>A study of the toxicity of the protamine, salmine</article-title><source>Br J Pharmacol Chemother</source><year>1949</year><volume>4</volume><issue>2</issue><fpage>135</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">18149707</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>MM</given-names></name><name><surname>Hill</surname><given-names>AB</given-names></name><name><surname>Nahrwold</surname><given-names>ML</given-names></name><name><surname>Tait</surname><given-names>AR</given-names></name></person-group><article-title>Effect of protamine on plasma ionized calcium in the
dog</article-title><source>Can Anaesth Soc</source><year>1982</year><volume>29</volume><issue>1</issue><fpage>65</fpage><lpage>67</lpage></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapira</surname><given-names>N</given-names></name><name><surname>Schaff</surname><given-names>HV</given-names></name><name><surname>Piehler</surname><given-names>JM</given-names></name><name><surname>White</surname><given-names>RD</given-names></name><name><surname>Still</surname><given-names>JC</given-names></name><name><surname>Pluth</surname><given-names>JR</given-names></name></person-group><article-title>Cardiovascular effects of protamine sulfate in
man</article-title><source>J Thorac Cardiovasc Surg</source><year>1982</year><volume>84</volume><issue>4</issue><fpage>505</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">7121041</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milne</surname><given-names>B</given-names></name><name><surname>Rogers</surname><given-names>K</given-names></name><name><surname>Cervenko</surname><given-names>F</given-names></name><name><surname>Salerno</surname><given-names>T</given-names></name></person-group><article-title>The hemodynamic effects of intraaortic versus intravenous
administration of protamine for reversal of heparin in man</article-title><source>Can Anaesth Soc J</source><year>1983</year><volume>30</volume><issue>4</issue><fpage>347</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">6871776</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frater</surname><given-names>RW</given-names></name><name><surname>Oka</surname><given-names>Y</given-names></name><name><surname>Hong</surname><given-names>Y</given-names></name><name><surname>Tsubo</surname><given-names>T</given-names></name><name><surname>Loubser</surname><given-names>PG</given-names></name><name><surname>Masone</surname><given-names>R</given-names></name></person-group><article-title>Protamineinduced circulatory changes</article-title><source>J Thorac Cardiovasc Surg</source><year>1984</year><volume>87</volume><issue>5</issue><fpage>687</fpage><lpage>692</lpage><pub-id pub-id-type="pmid">6609280</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakefield</surname><given-names>TW</given-names></name><name><surname>Hantler</surname><given-names>CB</given-names></name><name><surname>Lindblad</surname><given-names>B</given-names></name><name><surname>Whitehouse</surname><given-names>WM</given-names><suffix>Jr</suffix></name><name><surname>Stanley</surname><given-names>JC</given-names></name></person-group><article-title>Protamine pretreatment attenuation of hemodynamic and hematologic
effects of heparin-protamine interaction. A prospective randomized study in
human beings undergoing aortic reconstructive surgery</article-title><source>J Vasc Surg</source><year>1986</year><volume>3</volume><issue>6</issue><fpage>885</fpage><lpage>889</lpage><pub-id pub-id-type="pmid">3712636</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>WJ</given-names></name><name><surname>McSweeney</surname><given-names>SM</given-names></name><name><surname>Kellett</surname><given-names>MA</given-names></name><name><surname>Faxon</surname><given-names>DP</given-names></name><name><surname>Ryan</surname><given-names>TJ</given-names></name></person-group><article-title>Increased risk of severe protamine reactions in NPH
insulin-dependent diabetics undergoing cardiac
catheterization</article-title><source>Circulation</source><year>1984</year><volume>70</volume><issue>5</issue><fpage>788</fpage><lpage>792</lpage><pub-id pub-id-type="pmid">6488493</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirklin</surname><given-names>JK</given-names></name><name><surname>Chenoweth</surname><given-names>DE</given-names></name><name><surname>Naftel</surname><given-names>DC</given-names></name><name><surname>Blackstone</surname><given-names>EH</given-names></name><name><surname>Kirklin</surname><given-names>JW</given-names></name><name><surname>Bitran</surname><given-names>DD</given-names></name><etal/></person-group><article-title>Effects of protamine administration after cardiopulmonary bypass
on complement, blood elements, and the hemodynamic state</article-title><source>Ann Thorac Surg</source><year>1986</year><volume>41</volume><issue>2</issue><fpage>193</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">3947172</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horrow</surname><given-names>JC</given-names></name></person-group><article-title>Protamine: a review of its toxicity</article-title><source>Anesth Analg</source><year>1985</year><volume>64</volume><issue>3</issue><fpage>348</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">3883848</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hines</surname><given-names>RL</given-names></name><name><surname>Barash</surname><given-names>PG</given-names></name></person-group><article-title>Protamine: does it alter right ventricular
function?</article-title><source>Anesth Analg</source><year>1986</year><volume>65</volume><issue>12</issue><fpage>1271</fpage><lpage>1274</lpage><pub-id pub-id-type="pmid">3777455</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castresana</surname><given-names>MR</given-names></name><name><surname>Zhang</surname><given-names>LM</given-names></name><name><surname>Newman</surname><given-names>WH</given-names></name></person-group><article-title>Protamine does not affect the formation of cGMP or cAMP in pig
vascular smooth muscle cells in response to vasodilators</article-title><source>Crit Care Med</source><year>1995</year><volume>23</volume><issue>5</issue><fpage>939</fpage><lpage>943</lpage><pub-id pub-id-type="pmid">7736754</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panos</surname><given-names>A</given-names></name><name><surname>Orrit</surname><given-names>X</given-names></name><name><surname>Chevalley</surname><given-names>C</given-names></name><name><surname>Kalangos</surname><given-names>A</given-names></name></person-group><article-title>Dramatic post-cardiotomy outcome, due to severe anaphylactic
reaction to protamine</article-title><source>Eur J Cardiothorac Surg</source><year>2003</year><volume>24</volume><issue>2</issue><fpage>325</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">12895638</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lutjen</surname><given-names>DL</given-names></name><name><surname>Arndt</surname><given-names>KL</given-names></name></person-group><article-title>Methylene blue to treat vasoplegia due to a severe protamine
reaction: a case report</article-title><source>AANA J</source><year>2012</year><volume>80</volume><issue>3</issue><fpage>170</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">22848976</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Duca</surname><given-names>D</given-names></name><name><surname>Sheth</surname><given-names>SS</given-names></name><name><surname>Clarke</surname><given-names>AE</given-names></name><name><surname>Lachapelle</surname><given-names>KJ</given-names></name><name><surname>Ergina</surname><given-names>PL</given-names></name></person-group><article-title>Use of methylene blue for catecholamine-refractory vasoplegia
from protamine and aprotinin</article-title><source>Ann Thorac Surg</source><year>2009</year><volume>87</volume><issue>2</issue><fpage>640</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">19161806</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fettah</surname><given-names>ND</given-names></name><name><surname>Dilli</surname><given-names>D</given-names></name><name><surname>Cavusoglu</surname><given-names>H</given-names></name><name><surname>Beken</surname><given-names>S</given-names></name><name><surname>Ozgur</surname><given-names>S</given-names></name><name><surname>Zenciroglu</surname><given-names>A</given-names></name><etal/></person-group><article-title>Management of postoperative pulmonary hypertension by inhaled
nitric oxide in a newborn with congenital diaphragmatic
hernia</article-title><source>J Coll Physicians Surg Pak</source><year>2014</year><volume>24</volume><issue>9</issue><fpage>690</fpage><lpage>691</lpage><pub-id pub-id-type="pmid">25233978</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruzliak</surname><given-names>P</given-names></name><name><surname>Maruyama</surname><given-names>J</given-names></name><name><surname>Maruyama</surname><given-names>K</given-names></name></person-group><article-title>Role of nitric oxide in pathophysiology and treatment of
pulmonary hypertension</article-title><source>Vitam Horm</source><year>2014</year><volume>96</volume><fpage>407</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">25189396</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossaint</surname><given-names>R</given-names></name><name><surname>Lewandowski</surname><given-names>K</given-names></name><name><surname>Zapol</surname><given-names>WM</given-names></name></person-group><article-title>Our paper 20 years later: Inhaled nitric oxide for the acute
respiratory distress syndrome: discovery, current understanding, and
focussed targets of future applications</article-title><source>Intensive Care Med</source><year>2014</year><volume>40</volume><issue>11</issue><fpage>1649</fpage><lpage>1658</lpage><pub-id pub-id-type="pmid">25201565</pub-id></element-citation></ref></ref-list></back></article>